...
首页> 外文期刊>Annals of clinical biochemistry. >High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations.
【24h】

High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations.

机译:用于检测家族配体缺陷型载脂蛋白B-100突变的高分辨率熔解分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Familial ligand-defective apolipoprotein B-100 (FDB) is characterized by elevated plasma concentrations of LDL-cholesterol and apolipoprotein (apo) B, normal triglyceride and HDL-cholesterol levels, the presence of tendon xanthomas, and premature coronary artery disease. FDB cannot be clinically distinguished from heterozygous LDL-receptor-defective familial hypercholesterolaemia (FH) without genetic testing. METHODS: Amplicons in exon 26 and exon 29 of the APOB gene were screened for established genetic variants including mutations and polymorphisms using high-resolution melting analysis. Six novel variants associated with FDB in hypercholesterolaemic Dutch patients (S3476L, S3488G, Y3533C, T3540M, I4350T, G4368D) were also studied. RESULTS: All positive controls, a total of 10 mutations in exon 26 and four mutations in exon 29, were readily detectable by melting curve analysis. In addition, a patient previously not known to be heterozygous for the H3543Y mutation was identified in a screen of hypercholesterolaemic subjects. The method was validated by comparison of high-resolution melting analysis with DNA sequence data in a 'blinded' manner in 35 consecutive patients attending a lipid disorders clinic. These patients were classified as 'definite FH' by the Dutch Lipid Clinic Network criteria. Five patients were found to be heterozygous for the R3500Q and one for H3543Y. CONCLUSIONS: We have established a novel, robust method of FDB mutation detection using high-resolution melting analysis in conjunction with DNA sequencing. Compared with existing methods it is not only more cost-effective, but is also capable of detecting new sequence changes and will have importance in cascade screening of affected subjects.
机译:背景:家族性配体缺陷型载脂蛋白B-100(FDB)的特征在于血浆中LDL-胆固醇和载脂蛋白B的浓度升高,甘油三酯和HDL胆固醇水平正常,肌腱黄瘤的存在以及冠状动脉疾病的发生。如果没有基因检测,FDB在临床上不能与杂合的LDL受体缺陷型家族性高胆固醇血症(FH)区别开来。方法:使用高分辨率熔解分析筛选APOB基因第26外显子和第29外显子的扩增子,以建立已建立的遗传变异,包括突变和多态性。还研究了高胆固醇血症的荷兰患者中与FDB相关的六个新变体(S3476L,S3488G,Y3533C,T3540M,I4350T,G4368D)。结果:所有阳性对照,外显子26共有10个突变,外显子29共有4个突变,可通过熔解曲线分析轻松检测到。另外,在高胆固醇血症受试者的筛选中鉴定出先前未知的H3543Y突变杂合患者。该方法通过以盲法将高分辨率解链分析与DNA序列数据进行比较而得到验证,该方法以连续35例在脂质异常诊所就诊的患者进行。根据荷兰脂质临床网络标准,这些患者被分类为“确定性FH”。发现5例患者的R3500Q杂合子,1例H3543Y的杂合子。结论:我们建立了一种新颖的,健壮的FDB突变检测方法,该方法使用高分辨率熔解分析结合DNA测序。与现有方法相比,它不仅具有更高的成本效益,而且还能够检测新的序列变化,并且在级联筛选受影响受试者中将具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号